Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. DOGE Stimulus Checks ...
In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Vertex (VERX – Research Report), with a price ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Jefferies lowered the firm’s price target on Vertex (VERX) to $48 from $62 and keeps a Buy rating on the shares. The company’s results beat on ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsJoe Crivelli – Vice President of ...
Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...
KING OF PRUSSIA, Pa. (AP) — KING OF PRUSSIA, Pa. (AP) — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, ...
Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...
Vertex (VERX) delivered earnings and revenue surprises of 7.14% and 1.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...